Applied BioCode - Asset Resilience Ratio

Latest as of September 2025: 9.75%

Applied BioCode (6598) has an Asset Resilience Ratio of 9.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Applied BioCode to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$100.55 Million

≈ $3.17 Million USD Cash + Short-term Investments

Total Assets

NT$1.03 Billion

≈ $32.48 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Applied BioCode's Asset Resilience Ratio has changed over time. See 6598 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Applied BioCode's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 6598 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$100.55 Million	9.75%
Total Liquid Assets	NT$100.55 Million	9.75%

Asset Resilience Insights

Limited Liquidity: Applied BioCode maintains only 9.75% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Applied BioCode Industry Peers by Asset Resilience Ratio

Compare Applied BioCode's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Cochlear Ltd AU:COH	Medical Devices	9.76%
Shenzhen New Industries Biomedical SHE:300832	Medical Devices	9.95%
Jafron Biomedical Co Ltd SHE:300529	Medical Devices	39.15%
HOB Biotech Group Corp Ltd SHG:688656	Medical Devices	2.62%
Polynovo Ltd AU:PNV	Medical Devices	0.04%
Shanghai ZJ Bio-Tech Co. Ltd. A SHG:688317	Medical Devices	10.88%
Dirui Industrial Co Ltd SHE:300396	Medical Devices	6.89%
Emvision Medical Devices Ltd AU:EMV	Medical Devices	0.06%

Annual Asset Resilience Ratio for Applied BioCode (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Applied BioCode.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	20.70%	NT$251.53 Million ≈ $7.92 Million	NT$1.21 Billion ≈ $38.28 Million	+1.41pp
2023-12-31	19.29%	NT$191.62 Million ≈ $6.04 Million	NT$993.21 Million ≈ $31.29 Million	+2.42pp
2019-12-31	16.87%	NT$121.33 Million ≈ $3.82 Million	NT$719.01 Million ≈ $22.65 Million	+16.57pp
2018-12-31	0.30%	NT$1.54 Million ≈ $48.61K	NT$514.07 Million ≈ $16.20 Million	+0.04pp
2017-12-31	0.26%	NT$890.00K ≈ $28.04K	NT$336.83 Million ≈ $10.61 Million	-69.42pp
2016-12-31	69.69%	NT$333.63 Million ≈ $10.51 Million	NT$478.77 Million ≈ $15.08 Million	+50.99pp
2015-12-31	18.69%	NT$58.14 Million ≈ $1.83 Million	NT$310.99 Million ≈ $9.80 Million	+2.99pp
2014-12-31	15.71%	NT$55.70 Million ≈ $1.75 Million	NT$354.66 Million ≈ $11.17 Million	+4.16pp
2013-12-31	11.55%	NT$22.47 Million ≈ $707.93K	NT$194.56 Million ≈ $6.13 Million	+3.27pp
2012-12-31	8.28%	NT$21.79 Million ≈ $686.35K	NT$262.99 Million ≈ $8.29 Million	--

pp = percentage points

About Applied BioCode

TW:6598 Taiwan Medical Devices

Market Cap

$79.03 Million

NT$2.51 Billion TWD

Market Cap Rank

#20214 Global

#1201 in Taiwan

Share Price

NT$24.40

Change (1 day)

+0.00%

52-Week Range

NT$19.25 - NT$25.65

All Time High

NT$177.50